1-3 of 3
Alessandro Previtali
Close
Sort by
Journal Articles

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL

Clinical Trials & Observations
Jeremy S. Abramson, Patrick B. Johnston, Manali Kamdar, Sami Ibrahimi, Koji Izutsu, Jon Arnason, Bertram Glass, Pim Mutsaers, Matthew Lunning, Julia Braverman, Fei Fei Liu, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Shien Guo, Ling Shi, Scott R. Solomon
Journal: Blood Advances
Blood Adv (2022) 6 (23): 5969–5979.
https://doi.org/10.1182/bloodadvances.2022008106
Published: 2022
Includes: Supplemental data
Journal Articles

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

Clinical Trials & Observations
Amer M. Zeidan, Isaac Boss, C. L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa E. Hasle, Andrzej Hellmann, David C. Taussig, Mar Tormo, Maria Teresa Voso, James Cavenagh, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Lewis R. Silverman
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2219–2229.
https://doi.org/10.1182/bloodadvances.2021006138
Published: 2022
Includes: Supplemental data
Journal Articles

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

Clinical Trials & Observations
Amer M. Zeidan, Isaac Boss, C. L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa E. Hasle, Ken Ogasawara, James Cavenagh, Lewis R. Silverman, Maria Teresa Voso, Andrzej Hellmann, Mar Tormo, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Guillermo Garcia-Manero
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2207–2218.
https://doi.org/10.1182/bloodadvances.2021005487
Published: 2022
Includes: Supplemental data